[PDF][PDF] Burden of illness in hereditary periodic fevers: a multinational observational patient diary study

…, F Dedeoglu, HJ Lachmann, T Kallinich… - Clin Exp …, 2020 - clinexprheumatol.org
Objective. This study aimed to characterise the burden of illness of patients with inadequately
controlled hereditary periodic fevers (HPFs), during and outside of flares. It was focused on …

SIGLEC1 enables straightforward assessment of type I interferon activity in inflammatory myopathies

…, GR Burmester, F Hiepe, R Biesen, T Kallinich… - medRxiv, 2021 - medrxiv.org
Objective To evaluate SIGLEC1 expression on monocytes by flow cytometry as a type I
interferon biomarker in idiopathic inflammatory myopathies (IIM). Methods We performed a …

Trace element and cytokine concentrations in patients with Fibrodysplasia Ossificans Progressiva (FOP): A case control study

L Hildebrand, T Gaber, P Kühnen, R Morhart… - Journal of Trace …, 2017 - Elsevier
Tilman Kallinich for excellent assistance and insightful advice, and the people from the
laboratory of Petra Seemann and Andreas Kurtz for helpful discussions regarding the study. …

POS1204 LOW POSITIVITY RATE IN ANTIBODY SARS-COV2 TESTS IN PATIENTS WITH RHEUMATIC DISEASES TREATED WITH RITUXIMAB. A CASE CONTROL …

AG Fernández, PM Álvarez, J Bachiller-Corral, MV Díaz - 2021 - ard.bmj.com
Background: Diagnosis of previous SARS-COV2 infection may be challenging in
immunocompromised patients. Objectives: To analyze positivity rate to SARS-COV2 antibody tests (…

Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial

S Ozen, E Ben-Cherit, I Foeldvari, G Amarilyo… - Annals of the …, 2020 - ard.bmj.com
Objectives To evaluate the long-term efficacy and safety of canakinumab to treat patients with
colchicine-resistant familial Mediterranean fever (crFMF) during Epoch 4 (weeks 41 to 113) …

Early and rapid identification of COVID-19 patients with neutralizing type I-interferon auto-antibodies by an easily implementable algorithm

B Akbil, T Meyer, P Stubbemann, C Thibeault… - Medrxiv, 2021 - medrxiv.org
Purpose Six-19% of critically ill COVID-19 patients display circulating auto-antibodies against
type I interferons (IFN-AABs). Here, we establish a clinically applicable strategy for early …

[HTML][HTML] Protocols on classification, monitoring and therapy in children's rheumatology (PRO-KIND): results of the working group Polyarticular juvenile idiopathic …

G Horneff, A Klein, G Ganser, M Sailer-Höck… - Pediatric …, 2017 - Springer
Objective Several effective pharmacologic treatment options for polyarticual juvenile idiopathic
arthritis (JIA) have emerged but initial treatment is heterogeneous in Germany. Therefore, …

[BOOK][B] Popgeschichte: Band 2: Zeithistorische Fallstudien 1958-1988

B Mrozek, A Geisthövel, J Danyel - 2014 - degruyter.com
Kallinich/Bretthauer (Hg.): Botschaft der Dinge, S. 74; Von Lagerfeld bis Stan … Hausherr,
Tilman: Eine Reise nach Berlin im Jahr 1956, http://home.snafu.de/ tilman/Berlin-1956/ (4.1.2013)…

POS1202 EXPERIENCE WITH COVID-19 IN GERMAN PAEDIATRIC RHEUMATOLOGY CENTRES

A Klein, D Windschall, W Emminger, R Berendes… - 2021 - ard.bmj.com
Background: COVID-19 is a major challenge worldwide. Although the risk for a severe
disease course is low among children with COVID-19, symptoms may be exacerbated by …

[PDF][PDF] 6DZIF German Centre for Infection Research (DZIF), partner site Charité, 10117 Berlin, 24

M Akbil, T Stubbemann, C Tabeling, C Nusshag… - scholar.archive.org
… Lisa Ruby4, Claudia Zensen4, Mirja Mittermaier4, Fridolin Steinbeis4, Tilman
Lingscheid4, 546 …